2016

2016/01/14

Notice of change in the Company Name, consolidated subsidiary, United States-based Clontech Laboratories, Inc.

Kusatsu/Shiga, Japan – January 14, 2016 – The Board of Directors resolved today that its consolidated subsidiary, United States-based Clontech Laboratories, Inc. has changed the company name in January 2016 as follows.

 

1. Overview of the consolidated subsidiary

Name(Former)(New) Clontech Laboratories, Inc.Takara Bio USA, Inc.
Address 1290 Terra Bella Avenue Mountain View, CA 94043
President President, Carol Lou
Business outline Development and sales of research reagents
Capital 83,000 US dollars

 

2. Reason for the change

Takara Bio develops original three brands, “TaKaRa®”, “Clontech®”, and “Cellartis®” in the world’s bioindustry business for research reagents, scientific instruments, and contracted research services. The current change of the company name will enable to reinforce “Clontech®” as a brand of products and services and increase global awareness of Takara Bio.

 

For more information:Corporate Communications, Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp

This article is translated from press release in Japanese for your convenience.

Forward-Looking Statements
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

 

 

return to top